Drug Pipeline Database & Screener

Over 2000 drug entries from about 550 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

NASDAQ and NYSE stocks only are shown. OTC stocks are not covered on BioPharmCatalyst.

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates.

Financial data are delayed 15-25 minutes.

Showing 587 companies
Screener
Sort
Stage
Indication
Market Cap
Price
Short ratio
Relative Volume
Price to book
Company
Price
Change
No of Shares
Market Cap
Short Ratio
Updated
$86.98
+0.26  +0.30%
1.5 billion
$128.6 billion
8.84
12/06/2019
Tap to view 36 drugs
Drug Indication Stage News
Depatuxizumab mafodotin ABT-414 Glioblastoma (rGBM) Phase 3 Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.
Veliparib Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) Phase 3 Phase 3 trial did not meet primary endpoints - April 19, 2017.
Ibrutinib Relapsed or refractory MCL mantle cell lymphoma Approved Approved November 13, 2013.
Imbruvica Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy Approved Approved February 12, 2014.
Imbruvica Deletion 17p Approved Approved July 19, 2014.
VIEKIRA PAK HCV - genotype 1 Approved Approved December 19, 2014.
IMBRUVICA Waldenström’s Macroglobulinemia Approved Approved January 29, 2015 - PCYC
ABBV-8E12 Alzheimer's disease Phase 2 Phase 2 initiation announced January 25, 2017.
Venclexta (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) Approved Approval announced June 11, 2018.
Venetoclax - CANOVA Relapsed or refractory multiple myeloma Phase 3 Phase 3 data due in 2021.
Risankizumab Psoriasis Approved FDA approval announced April 23, 2019.
Imbruvica Second-line Chronic graft-versus-host disease (GVHD) Approved Approval announced August 2, 2017.
ABT-494 Psoriatic Arthritis Phase 3 Phase 3 trial to commenced 2017.
Rova-T (TRINITY) Third-line Small Cell Lung Cancer Phase 2 Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
Upadacitinib Atopic Dermatitis Phase 3 Phase 3 trial met primary and secondary endpoints - October 31, 2019.
Imbruvica Marginal zone lymphoma Approved sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV) Approved Approval announced August 3, 2017.
Elagolix Uterine Fibroids NDA Filing NDA filing announced August 5, 2019.
Elagolix Endometriosis Approved FDA approval announced July 24, 2018.
ABT-494 upadacitinib Rheumatoid arthritis Approved FDA Approval announced August 16, 2019.
Rova-T (TAHOE) Second-line Small Cell Lung Cancer Phase 3 Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (MERU) First-line Small Cell Lung Cancer Phase 3 Phase 3 trial demonstrated no survival benefit at interim analysis - October 29, 2019.
Imbruvica and Gazyva - iLLUMINATE Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) Approved FDA approval announced January 28, 2019.
IMBRUVICA (ibrutinib) Waldenström’s Macroglobulinemia Approved FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib) Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Venclexta First line unfit AML Approved FDA approval announced November 21, 2018.
Upadacitinib - U-ACHIEVE Ulcerative colitis Phase 2/3 Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Venetoclax and obinutuzumab Chronic Lymphocytic Leukemia Phase 3 FDA approval announced May 15, 2019.
Ibrutinib (Imbruvica) Pancreatic cancer Phase 3 Phase 3 primary endpoint not met (PFS/OS).
Venclexta plus Gazyva Chronic lymphocytic leukemia (CLL) Phase 3 Phase 3 data presented at ASCO June 4, 2019. HR 0.35. CRR 49.5%. ORR 84.7% vs. 71.3%.
Venclexta MIRROS Acute myeloid leukemia (AML) Phase 3 Phase 3 data due 2H 2019.
Venclexta BELLINI Multiple myeloma Phase 3 Phase 3 primary endpoint met.
Venetoclax and obinutuzumab Chronic lymphocytic leukemia sNDA Filing sNDA filing announced June 4, 2019.
Veliparib Ovarian cancer Phase 3 Phase 3 presentation at ESMO 28 September 2019.
Risankizumab ( LIMMITLESS ) Psoriasis Phase 3 Phase 3 data presented at EADV October 10, 2019.
IMBRUVICA (ibrutinib) and rituximab Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). sNDA Filing sNDA filing announced November 8, 2019.
$3.00
+0.24  +8.70%
51.2 million
$153.5 million
12/06/2019
Tap to view 4 drugs
Drug Indication Stage News
ABO-101 Sanfilippo syndrome type B (MPS IIIB) Phase 1/2 Phase 1/2 interim data due 2H 2019.
EB-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 1/2 Phase 3 trial initiation placed on clinical hold.
ABO-102 Sanfilippo syndrome type A (MPS IIIA) Phase 1/2 Phase 1/2 presentation at ESGCT October 25, 2019.
ABO-202 CLN1 disease (Infantile Batten disease) Phase 1/2 Phase 1/2 trial planned. Timing to be announced later in 2019.
$5.30
-0.12  -2.21%
1.6 million
$8.4 million
12/06/2019
Tap to view 1 drug
$2.29
+0.07  +3.15%
56.9 million
$130.2 million
12/06/2019
Tap to view 4 drugs
Drug Indication Stage News
ARB-1467, tenofovir, and pegylated interferon Hepatitis B (HBV) Phase 2 Phase 2 trial ongoing but no plans to continue further development.
AB-452 Hepatitis B Phase 1 Decision regarding clinical development due early 2020.
AB-506 Hepatitis B (HBV) Phase 1 Development to be discontinued - noted October 3, 2019.
AB-729 Hepatitis B (HBV) Phase 1 Phase 1a/b data due 1Q 2020.
$51.40
+0.92  +1.82%
154 million
$7.9 billion
12/06/2019
Tap to view 7 drugs
Drug Indication Stage News
Pimavanserin - CLARITY-2 Adjunctive Treatment in Patients With Major Depressive Disorder Phase 3 Phase 3 trial initiation announced April 25, 2019.
Pimavanserin - Advance Adjunctive treatment in patients with negative symptoms of schizophrenia Phase 2 Phase 2 data released November 25, 2019. Primary endpoint met. Key secondary missed. Further pivotal trial to be initiated 2H 2020.
Pimavanserin - Enhance Adjunctive treatment of schizophrenia Phase 3 Phase 3 data did not meet primary endpoint - July 22, 2019.
Pimavanserin - SERENE Alzheimer’s disease agitation Phase 2 Announced October 4, 2017 that trial will be discontinued.
Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin - Harmony Alzheimer’s disease psychosis Phase 3 Phase 3 trial stopped early after meeting primary endpoint - September 9, 2019. Data presented at CTAD meeting December 4, 2019 noted HR =0.353, one-sided p=0.0023.
Trofinetide Rett Syndrome Phase 3 Phase 3 trial initiation announced October 30, 2019.
$3.67
+0.09  +2.51%
10.1 million
$37 million
12/06/2019
Tap to view 4 drugs
Drug Indication Stage News
EDSIVO Vascular Ehlers-Danlos Syndrome CRL CRL issued June 25, 2019.
Tovaxin (Tcelna) Secondary Progressive MS (SPMS) Phase 2b Phase 2b trial did not meet primary endpoint - October 28, 2016.
ACER-001 Urea cycle disorder (UCD) Phase 2 Pivotal bioavailability and bioequivalence trial Part A data due 4Q 2019; Part B due 1Q 2020 with NDA filing 1Q 2021.
Osanetant induced Vasomotor Symptoms (iVMS) Phase 1/2 Phase 1/2 trial to be initiated mid-2020.
$6.17
+0.02  +0.33%
140.1 million
$864.4 million
12/06/2019
Tap to view 5 drugs
Drug Indication Stage News
ACH-4471 C3 glomerulopathy (C3G) Phase 2 Phase 2 completion due 2020.
JNJ-4178 Hepatitis C (HCV) Phase 2a Janssen noted September 11, 2017 that no further development planned.
Danicopan (ACH-4471) Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 presentation at ASH December 9, 2019 at 6pm ET.
JNJ-4178 - OMEGA-1 Hepatitis C (HCV) Phase 2b Janssen noted September 11, 2017 that no further development planned.
ACH-5228 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1 Phase 2 trial planned to commence 1H 2020.
$0.91
-0.05  -5.20%
8.4 million
$7.6 million
12/06/2019
Tap to view 1 drug
Drug Indication Stage News
Cytisine Smoking cessation Phase 2b Phase 2b data met primary endpoint in 3/4 arms - June 11, 2019.
$8.78
+0.59  +7.20%
67.6 million
$593.2 million
12/06/2019
Tap to view 9 drugs
Drug Indication Stage News
Crenezumab - CREAD 2 Alzheimer’s disease Phase 3 Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
RG6100 (Anti-Tau RO7105705) Alzheimer’s disease Phase 2 Phase 2 data due 3Q 2020.
ACI-24 (anti-Abeta vaccine) Alzheimer's disease-like characteristics in individuals with Down syndrome Phase 1/2 Phase 1/2 interim data released July 2019.
Crenezumab - CREAD 1 Alzheimer’s disease Phase 3 Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
ACI-24 Alzheimer’s disease Phase 2 Phase 2 trial initiation announced August 20, 2018.
MTAU9937A Alzheimer’s disease Phase 2 Phase 2 trial initiation announced February 20, 2019.
ACI-35 Alzheimer’s disease Phase 1b Phase 2 trial planned for 1H 2019.
ACI-3024 Alzheimer’s disease Phase 1 Phase 1 trial initiation announced July 17, 2019.
ACI-35.030 Alzheimer’s Disease Phase 1/2 Phase 1b/2 trial initiation announced August 1, 2019.
$1.71
+0.01  +0.59%
48 million
$82.1 million
12/06/2019
Tap to view 6 drugs
$1.66
+0.04  +2.47%
41.4 million
$68.7 million
12/06/2019
Tap to view 8 drugs
Drug Indication Stage News
ATI-502 (ATI-50002-AA-201) - dose ranging Alopecia areata Phase 2 Phase 2 data did not meet primary endpoint - June 26, 2019.
ATI-502 (VITI-201 Topical) Vitiligo Phase 2 Development to be discontinued - noted August 8, 2019.
ATI-501 (AUAT-201 Oral) Alopecia areata Phase 2 Phase 2 data met primary endpoint and some secondary endpoints - July 30, 2019. Partner required for further development.
ESKATA (hydrogen peroxide) Seborrheic keratosis (SK) Approved Approval announced December 15, 2017.
A-101 THWART-1 and THWART-2 Common warts (verruca vulgaris) Phase 3 Phase 3 data met all endpoints - September 16, 2019 and October 24, 2019.
ATI-502 Androgenetic alopecia (AGA) - Hair loss Phase 2 Partner required to further development.
ATI-502 (AD-201 Topical) Atopic dermatitis (AD) Phase 2 Phase 2 trial completed.
ATI-450 Rheumatoid arthritis (RA) Phase 1/2 Phase 1 data due 4Q 2019 or 1Q 2020.
$1.87
+0.04  +2.19%
79.6 million
$148.8 million
12/06/2019
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
DSUVIA (ARX-04) Moderate-to-severe acute pain following a surgical procedure Approved FDA Approval announced November 2, 2018.
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. NDA resubmission timing to be known in 2H 2019.
$1.86
-0.04  -2.11%
85.2 million
$158.7 million
12/06/2019
Tap to view 1 drug
Drug Indication Stage News
CaPre (TRILOGY 1 and 2) Hypertriglyceridemia Phase 3 Phase 3 top-line data due in December 2019 (1) and late-January 2020 (2).
$1.12
-0.02  -1.75%
105.2 million
$117.8 million
12/06/2019
Tap to view 5 drugs
Drug Indication Stage News
MAGE-A4 (ADP-A2M4) Soild tumors Phase 1 Phase 1 updated data at CTOS November 16, 2019 - ORR 7/14.
AFP (ADP-A2AFP) Hepatocellular carcinoma Phase 1 Phase 1 data update due 1H 2020.
MAGE-A10 (ADP-A2M10) Non-Small Cell Lung Cancer (NSCLC) Phase 1 Phase 1 further data due 2H 2019.
MAGE-A4 (SPEARHEAD‑1) Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) Phase 2 Phase 2 interim futility data due 1H 2020.
MAGE-A4 (ADP-A2M4CD8 - SURPASS) Soild tumors Phase 1 Phase 1 safety and response data due 1H 2020.
$1.51
+0.13  +9.34%
10.3 million
$15.6 million
12/06/2019
Tap to view 1 drug
$4.32
+0.19  +4.60%
59.3 million
$256.3 million
12/06/2019
Tap to view 2 drugs
Drug Indication Stage News
RI-002 Primary Immune Deficiency Diseases Approved FDA Approval announced April 1, 2019.
BIVIGAM Primary humoral immunodeficiency CRL Response to Complete Response Letter submitted January 7, 2019.
$0.55
  +0.62%
61.6 million
$34.1 million
12/06/2019
Tap to view 5 drugs
Drug Indication Stage News
Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. Approved CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
APC-1000 Asthma/COPD Phase 2 Phase 3 development on hold - noted May 9, 2019.
Symjepi - low dose Anaphylaxis Approved FDA Approval announced September 27, 2018.
Higher Dose Naloxone Injection Opioid overdose CRL CRL announced November 25, 2019.
APC-8000 (sublingual tadalafil) Erectile dysfunction NDA Filing Refusal to file letter received February 26, 2019.
$6.47
-0.04  -0.69%
27.9 million
$180.4 million
12/06/2019
Tap to view 5 drugs
Drug Indication Stage News
ADS-4101 Partial onset seizures in patents with epilepsy Phase 1b Further development deferred - noted May 9, 2019.
GOCOVRI (amantadine) Multiple sclerosis (MS) Phase 3 Phase 3 data due 4Q 2019.
Namzaric Moderate to severe dementia of the Alzheimer's type. Approved Approved December, 24 2014.
ADS-5102 Levodopa-Induced Dyskinesia Approved Approval announced August 24, 2017.
GOCOVRI (amantadine) Dyskinesia patients with Parkinson's disease Phase 3 Phase 3 open-label data released April 19, 2018.
$1.15
-0.03  -2.54%
80.5 million
$92.6 million
12/06/2019
Tap to view 12 drugs
Drug Indication Stage News
ADU-S100 Solid tumors or lymphomas Phase 1b Initial data at SITC November 2018 noted 2/40 PRs and 11 with SD.
CRS-207 and GVAX Pancreas - ECLIPSE trial Pancreatic cancer Phase 2b Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial Pancreatic cancer Phase 2b Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 with pembrolizumab Mesothelioma - cancer Phase 2 Noted December 12, 2017 that development to be discontinued.
pLADD Colorectal Cancer Phase 1 Phase 1 ongoing.
pLADD Colorectal Cancer Phase 1 Phase 1 ongoing.
ADU-214 with Nivolumab Non-Small Cell Lung Cancer Phase 1/2 Phase 1b initiation announced June 7, 2018.
ADU-S100 and Spartalizumab Solid tumors or lymphomas Phase 1b Phase 1 final data due 2020.
ADU-S100 and ipilimumab Melanoma Phase 1 Phase 1 commencement of dosing announced February 11, 2019.
BION-1301 IgA Nephropathy Phase 1 Phase 1 data due 2020.
ADU-S100 and pembrolizumab Squamous Cell Carcinoma of the Head and Neck (SCCHN) Phase 1/2 Phase 1b/2 initiation of dosing announced September 4, 2019 with initial data due 2020.
MK-5890 and pembrolizumab Solid tumors Phase 1 Phase 1 data presented at SITC November 2019 noted one patient in each of the monotherapy and combo arms showed a partial response.
$11.43
+0.89  +8.39%
64.6 million
$738.2 million
12/06/2019
Tap to view 3 drugs
Drug Indication Stage News
ADVM-043 Alpha-1 Antitrypsin (A1AT) Deficiency Phase 1/2 Development to be discontinued - noted November 1, 2018.
AVA-101 Wet age-related macular degeneration (Wet-AMD) Phase 2a Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
ADVM-022 Wet age-related macular degeneration (Wet-AMD) Phase 1 Phase 1 third cohort to commence enrolment in 4Q 2019. Cohort 1 52-week data and Cohort 2 24-week data due 1H 2020.
$0.77
+0.14  +21.75%
24.7 million
$19 million
12/06/2019
Tap to view 7 drugs
Drug Indication Stage News
Axalimogene filolisbac + durvalumab Recurrent or refractory HPV-associated cervical cancer and head & neck cancer Phase 1/2 Enrollment to be terminated - noted November 2, 2018.
ADXS-PSA and Keytruda - KEYNOTE-046 Castrate-resistant prostate cancer Phase 1/2 Phase 1 updated data noted median overall survival of 33.6 months - October 7, 2019.
Axalimogene filolisbac - AIM2CERV Trial High-risk, locally advanced cervical cancer Phase 3 Phase 3 trial closed - noted June 27, 2019.
ADXS-HER2 HER2-driven malignancies - cancer Phase 1b Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
Axalimogene filolisbac Anal cancer (FAWCETT) Phase 2 Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
ADXS-NEO Non-small cell lung cancer (NSCLC) Phase 1 Phase 1 safety and immunogenicity data presented at AACR March 2019
ADXS-HOT 503 Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 immune response data from Part A monotherapy due early 2020.
$19.86
+0.52  +2.66%
46.3 million
$920.2 million
12/06/2019
Tap to view 6 drugs
Drug Indication Stage News
Roclatan Glaucoma Approved FDA Approval announced March 12, 2019.
Rhopressa Glaucoma Approved PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
AR-13503 Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) Phase 1/2 Phase 1/2 trial initiation announced August 20, 2019.
AR-1105 Macular edema due to RVO (retinal vein occlusion) Phase 2 Phase 2 trial initiated March 2019.
Roclatan - Mercury 3 Open Angle Glaucoma Phase 3 Phase 3 top-line data due 1H 2020.
AVX-012 Dry eye disease Phase 2b Phase 2b trial to be initiated late-2020.
$0.86
-0.01  -1.72%
20 million
$17.1 million
12/06/2019
Tap to view 2 drugs
Drug Indication Stage News
Macimorelin Acetate - Macrilen Adult Growth Deficiency Approved CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Zoptrex Endometrial cancer Phase 3 Phase 3 trial did not meet primary endpoint - May 1, 2017.
$2.28
-0.03  -1.30%
76.2 million
$173.8 million
12/06/2019
Tap to view 5 drugs
Drug Indication Stage News
AFM13 with Keytruda Hodgkin Lymphoma - Cancer Phase 1b Phase 1b updated data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%.
AFM13 Hodgkin Lymphoma - Cancer Phase 2 Phase 2a ongoing.
AFM13 CD30-positive peripheral T cell lymphoma (PTCL) Phase 2 Phase 2 dosing has been initiated - noted November 19, 2019.
AFM11 Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) Phase 1 Phase 1 program terminated - noted May 22, 2019.
AFM24 EGFR-expressing solid tumors Phase 1/2 Phase 1/2a trial to commence 1Q 2020.
$3.91
-0.16  -3.93%
137.4 million
$537.1 million
12/06/2019
Tap to view 5 drugs
Drug Indication Stage News
AGEN2034 and AGEN1884 Solid tumors Phase 1/2 Phase 1/2 data due 2019.
AGEN1884 (anti-CTLA-4) Solid cancers Phase 1 Phase 1 data due 2019.
Shingrix Shingles Approved Approval announced October 20, 2017.
AGEN2034 (anti-PD-1) Cervical cancer Phase 1/2 Subset analysis of Phase I dose escalation trial presented at SITC November 8, 2019.
AGEN1181 - 2nd gen CTLA Advanced cancer Phase 1 Phase 1 data due 2019.
$40.94
+0.86  +2.15%
68.4 million
$2.8 billion
12/06/2019
Tap to view 17 drugs
Drug Indication Stage News
AG-348 - Mitapivat Thalassemia Phase 2 Phase 2 data due 4Q 2019.
Ivosidenib IDH1m Relapsed/Refractory AML - cancer Approved FDA Approval announced July 20, 2018.
AG-348 (ACTIVATE) Pyruvate kinase deficiency Phase 3 Phase 3 enrolment to be completed 2019.
AG-120 and VIDAZA - AGILE Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 enrolment to be completed 2020.
Enasidenib (AG-221) - IDHENTIFY Refractory Acute myeloid leukemia (AML) - cancer Phase 3 Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
IDHIFA (enasidenib) - AG-221 Advanced hematologic malignancies with an IDH2 mutation Approved Approval announced August 1, 2017.
AG-120 Ivosidenib IDH1 mutant positive cholangiocarcinoma - cancer Phase 3 sNDA filing due to be filed following final overall survival analysis mid-2020.
AG-120 Ivosidenib R/R Acute Myeloid Leukemia (AML) Phase 1 Phase 1 data at ASCO June 2018 noted CR rate was 24%.
Enasidenib or ivosidenib with VIDAZA Frontline AML with IDH1 or IDH2 mutation Phase 1/2 Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%.
Ivosidenib or enasidenib Frontline AML with IDH1 or IDH2 mutation Phase 1 Phase 1 updated data at ASH December 2018. CR+CRi/CRp 80%.
AG-270 Solid tumors Phase 1 Phase 1 data presented at AACR-NCI-EORTC October 27, 2019. Trial is ongoing.
Vorasidenib (AG-881) Glioma Phase 3 Phase 3 trial to be initiated YE 2019.
Ivosidenib Frontline AML with IDH1 mutation Approved FDA Approval announced May 2, 2019.
Ivosidenib and Vorasidenib (AG-881) IDHm low-grade glioma Phase 1 Phase 1 updated data noted 31% ORR with postoperative treatment - November 22, 2019.
Ivosidenib IDH1 mutant newly diagnosed AML ineligible for standard therapies Phase 1 Phase 1 updated data at ASCO June 3, 2019. 30% CR rate.
Ivosidenib and azacitidine ( Vidaza) Newly diagnosed AML with an IDH1 mutation Phase 1 Phase 1 updated data at ASH December 9, 2019 at 10:30 a.m. ET.
AG-348 - Mitapivat (DRIVE) Pyruvate Kinase Deficiency Phase 2 Phase 2 data to be presented at ASH December 9, 2019 from 6pm ET.
$7.88
+0.14  +1.81%
29 million
$228.4 million
12/06/2019
Tap to view 6 drugs
Drug Indication Stage News
AEB1102 Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS) Phase 1 Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
Pegzilarginase (AEB1102) Arginase I deficiency Phase 3 Phase 3 trial initiation announced June 3, 2019 with data due 1Q 2021.
AEB1102 Solid tumors Phase 1 Phase 1 dose escalation data presented at AACR April 15, 2018.
Pegzilarginase (AEB1102) Solid tumors Phase 1 Phase 1 data presented at ESMO October 2018 noted 1/28 PRs and 8/23 SD.
Pegzilarginase (AEB1102) + KEYTRUDA Small cell lung cancer (SCLC) Phase 2 Phase 1/2 top-line data due 1H 2020.
AEB4104 Homocystinuria Phase 1/2 Phase 1/2 trial to be initiated 2Q 2020 with initial data due 1Q 2021.
$186.37
+0.29  +0.16%
328.3 million
$61.2 billion
4.48
12/06/2019
Tap to view 32 drugs
Drug Indication Stage News
Botox Forehead lines Approved Approval (third indication) announced October 3, 2017.
RTGel in combination with BOTOX Overactive Bladder (OAB) Phase 2 Phase 2 trial to be completed 2H 2019.
JUVÉDERM VOLLURE Correction of moderate to severe facial wrinkles and folds Approved Approval announced March 20, 2017.
Brazikumab Crohn's disease Phase 3 Phase 3 ongoing.
Botox Depression Phase 2 Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
RORγt agonist Psoriasis Phase 2b Phase 2b trial ongoing.
Cariprazine Maintenance Treatment of Schizophrenia Approved Approval announced November 13, 2017.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma BLA Filing BLA filing due 1Q 2020.
ATOGEPANT Chronic migraine Phase 3 Phase 3 data due in 2020.
RAPASTINEL Major depressive disorder (MDD) Phase 3 Phase 3 trials did not meet primary endpoints - March 6, 2019.
RELAMORELIN Diabetic Gastroparesis Phase 3 Phase 3 top-line data due 2020.
ESMYA (ulipristal acetate) Uterine Fibroids CRL CRL issued August 21, 2018.
ABICIPAR Diabetic macular edema (DME) Phase 3 Phase 3 trial to be initiated 2019.
Cenicriviroc (CVC) Nonalcoholic steatohepatitis (NASH) Phase 3 Phase 3 data due 2020.
ABICIPAR Age-related macular degeneration (AMD) PDUFA priority review BLA acceptance of filing announced September 9, 2019. Estimated PDUFA date July 9, 2020.
AVYCAZ (ceftazidime and avibactam) Complicated Urinary Tract Infections (cUTI) Approved sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
Oxymetazoline HCl cream 1.0% Facial Erythema (Redness) Associated with Rosacea Approved Approved January 19, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults Chronic idiopathic constipation (CIC) Approved sNDA approval announced January 26, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) Approved Approved September 14, 2017.
Sarecycline Severe acne vulgaris Approved FDA Approval announced October 2, 2018.
Cariprazine Bipolar I Depression PDUFA FDA Approval announced May 28, 2019.
UBROGEPANT Migraine PDUFA NDA acceptance announced March 11, 2019. PDUFA December 2019. No exact date provided.
Brazikumab Ulcerative colitis Phase 2/3 Phase 2/3 trial ongoing.
Brimo DDS Geographic atrophy Phase 3 Phase 3 trial to be initiated 2H 2018.
Bimatoprost Open-angle glaucoma or ocular hypertension PDUFA PDUFA date 1H 2020. No exact date announced. Estimate May 15, 2020.
AVYCAZ (ceftazidime and avibactam) Complicated Urinary Tract Infections (cUTI) - pediatric Approved FDA Approval announced March 18, 2019.
Botox Lower limb spasticity Approved FDA Approval announced October 24, 2019.
Botox Upper limb spasticity Approved FDA Approval announced June 21, 2019.
AGN-241751 Major Depressive Disorder (MDD) Phase 2 Phase 2 top-line data due 2H 2019.
Presbysol Presbyopia Phase 3 Phase 3 top-line data due 2020.
RAPASTINEL Depression Phase 2 Phase 2 monotherapy interim analysis 2H 2019.
Juvéderm VOLUMA Mid-Face Injection Via Cannula Approved FDA Approval announced September 3, 2019.
$2.06
+0.03  +1.48%
59.3 million
$122.2 million
12/06/2019
Tap to view 1 drug
$2.87
-0.11  -3.69%
18.2 million
$52.3 million
12/06/2019
Tap to view 3 drugs
Drug Indication Stage News
AAV Gene Therapy Achromatopsia Phase 1/2 Phase 1/2 interim dose-escalation data due January 2020.
rAAV-hRS1 X-linked retinoschisis (XLRS) Phase 1/2 Phase 1/2 interim data released December 12, 2018. No signs of clinical activity.
AAV-based gene therapy X-linked Retinitis Pigmentosa (XLRP) Phase 1/2 Phase 1/2 dose expansion data due January 2020.
$0.40
-0.01  -2.71%
8.3 million
$3.3 million
0.23
12/06/2019
Tap to view 6 drugs
Drug Indication Stage News
Ampligen CFS CRL CRL February 4, 2013.
Ampligen, Intron A, celecoxib and pembrolizumab Triple-Negative Breast Cancer Phase 1 Phase 1 data due around 2Q 2020.
Ampligen, Intron A, and celecoxib Colorectal cancer Phase 2 Phase 2 interim data due around 2Q 2020.
Ampligen, cisplatin and pembrolizumab Ovarian cancer Phase 2 Phase 2 interim data due around 4Q 2020.
Ampligen, Intron A Prostate Cancer Phase 2 Phase 2 trial to commence enrolment in 4Q 2019.
Ampligen plus Intron A Ovarian cancer Phase 1/2 Phase 1 interim data to be presented 1Q 2020.
$29.65
+0.52  +1.79%
63.3 million
$1.9 billion
12/06/2019
Tap to view 6 drugs
Drug Indication Stage News
AR101 ARTEMIS Peanut Allergy Phase 3 Phase 3 trial met primary endpoint - March 25, 2019.
AR101 RAMSES Peanut Allergy Phase 3 Phase 3 data released November 8, 2018 noted no serious adverse events
AR101 Peanut Allergy PDUFA PDUFA date late-January 2020. Advisory Committee meeting September 13, 2019 voted in favor of supporting approval.
AR 201 Egg Allergy Phase 2 Phase 2 trial to be completed 2H 2020.
AR101 with adjunctive dupilumab Peanut Allergy Phase 2 Phase 2 trial initiation announced October 15, 2018.
AR101 POSEIDON Peanut Allergy Phase 3 Phase 3 data due 2020.
$5.91
-0.15  -2.48%
118.9 million
$703 million
12/06/2019
Tap to view 6 drugs
Drug Indication Stage News
Vadadustat - TRILO2GY Three-times-weekly dosing regimen for vadadustat Phase 3 Phase 3 trial to be initiated in 2019.
Vadadustat - FO2RWARD Renal anemia Phase 2 Phase 2 trial data due 2019.
Auryxia Hyperphosphatemia Approved Approved Sept 5, 2014.
Vadadustat - INNO2VATE Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD) Phase 3 Phase 3 data due 2Q 2020.
Vadadustat - PRO2TECT Non-dialysis patients with anemia related to CKD (NDD-CKD) Phase 3 Phase 3 data due mid-2020.
Auryxia Iron deficiency anemia in non-dialysis dependent CKD patients Approved sNDA FDA Approval announced November 7, 2017.
$17.64
+0.03  +0.17%
93.9 million
$1.7 billion
12/06/2019
Tap to view 9 drugs
Drug Indication Stage News
AKCEA-ANGPTL3-LRx Rare hyperlipidemias Phase 2 Pilot study data due mid-2019.
AKCEA-ANGPTL3-LRx Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus Phase 2b Phase 2 data due early 2020.
AKCEA-APOCIII-LRx Hyperlipoproteinemia and established cardiovascular disease Phase 2b Phase 2b data due early 2020.
AKCEA-APO(a)-LRx Hyperlipoproteinemia(a) and established cardiovascular disease Phase 2b Phase 3 trial to be initiated 2H 2019.
Inotersen (IONIS-TTRRx) NEURO-TTR - familial amyloid polyneuropathy (FAP). Approved FDA Approval announced October 5, 2018,
Volanesorsen - APPROACH Familial chylomicronemia syndrome (FCS) CRL CRL issued August 27, 2018.
Volanesorsen Partial lipodystrophy rapidly Phase 3 Phase 3 initiated November 2015
Volanesorsen Familial partial lipodystrophy (FPL) Phase 3 Phase 3 data met primary endpoint - August 6, 2019.
AKCEA-TTR-LRx hATTR Amyloidosis Phase 3 Phase 3 trial initiation announced November 25, 2019.
$22.99
+0.93  +4.22%
28.6 million
$656.6 million
12/06/2019
Tap to view 1 drug
Drug Indication Stage News
AKR-001 Nonalcoholic steatohepatitis (NASH) Phase 2a Phase 2a data due 1Q 2020.
$1.98
  +0.00%
21 million
$41.6 million
12/06/2019
Tap to view 4 drugs
Drug Indication Stage News
Coversin - CAPSTONE Paroxysmal nocturnal hemoglobinuria (PNH) Phase 3 Phase 3 staged readouts - no definitive timeline set by company. 2019?
Coversin Atopic keratoconjunctivitis Phase 1/2 Phase 1/2 Part B data due 4Q 2019.
Coversin Bullous Pemphigoid Phase 2 Phase 2 data presented at EADV Congress with a pivotal trial to commence 2H 2020.
Coversin Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) Phase 3 Phase 3 trial to commence by end of 2019.
$20.81
-0.59  -2.76%
12.7 million
$264 million
12/06/2019
Tap to view 3 drugs
Drug Indication Stage News
Odevixibat (A4250) - PEDFIC- 1 Progressive familial intrahepatic cholestasis (PFIC) Phase 3 Phase 3 top-line data due mid-2020.
Elobixibat Nonalcoholic steatohepatitis (NASH) Phase 2 Phase 2 data due mid-2020.
Odevixibat (A4250) Biliary atresia Phase 3 Phase 3 trial planned for 2020.
$0.00
  +0.00%
83.6 million
$
11/29/2019
Tap to view 5 drugs
$4.73
-0.1  -1.97%
28 million
$132.2 million
12/06/2019
Tap to view 6 drugs
Drug Indication Stage News
ADX-102 - topical ocular reproxalap - RENEW Dry eye syndrome Phase 3 Phase 3 (Part 1) data December 3, 2019 noted one co-primary endpoint was met while the other missed. Part 2 to be initiated 1H 2020.
Reproxalap (ADX-102) - INVIGORATE Allergic conjunctivitis Phase 3 Phase 3 trial to be initiated 1H 2020.
ADX-102 reproxalap Noninfectious anterior uveitis Phase 3 Phase 3 data did not meet endpoints - June 25, 2019.
Reproxalap (ADX-102) Sjögren-Larsson Syndrome (SLS) Phase 3 Phase 3 Part 1 section of trial completed.
ADX-1612 (ganetespib) Post-transplant lymphoproliferative disorder Phase 2 Phase 2 trial to be initiated 4Q 2019.
ADX-2191 Proliferative vitreoretinopathy (PVR) Phase 3 Phase 3 trial to be initiated 4Q 2019 with initial data due 2020.
$19.76
+0.37  +1.91%
68.9 million
$1.4 billion
12/06/2019
Tap to view 3 drugs
Drug Indication Stage News
AL001 Frontotemporal Dementia Phase 1 Phase 2 trial initiation announced September 9, 2019.
AL002 Alzheimer’s disease Phase 1 Phase 1 data presented at CTAD December 6, 2019 - generally safe and well-tolerated.
AL003 Alzheimer’s disease Phase 1 Phase 1 trial initiation announced April 3, 2019.
$7.52
+0.75  +11.08%
5 million
$37.3 million
12/06/2019
Tap to view 1 drug
Drug Indication Stage News
Iluvien Diabetic macular edema Approved CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
$20.95
+0.3  +1.45%
157.5 million
$3.3 billion
12/06/2019
Tap to view 13 drugs
Drug Indication Stage News
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD) Schizophrenia Approved FDA approval announced July 2, 2018.
ALKS 3831 - ENLIGHTEN-2 Schizophrenia, bipolar NDA Filing NDA filing announced November 19, 2019.
BYDUREON Type 2 diabetes Approved CRL received March 15, 2010.
Aristada Schizophrenia Approved Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Diroximel fumarate (BIIB098) Multiple sclerosis (MS) Approved FDA Approval announced October 30, 2019.
ALKS 6428 Opioid dependence Phase 3 Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 5461 Major depressive disorder CRL CRL announced February 1, 2019.
ALKS 3831 - ENLIGHTEN-1 Schizophrenia Phase 3 Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 4230 ARTISTRY-1 Solid tumors Phase 1 Phase 1/2 data at SITC November 2019 - 8/14 SD for monotherapy, 12/18 for combo (incl. 2 PRs).
Aristada and Invega Sustenna Schizophrenia Phase 3 Phase 3 data released April 9, 2019 - primary endpoint met.
ALKS 4230 + Keytruda - ARTISTRY-2 Solid tumors Phase 1 Phase 1 data presented at SITC November 8, 2019.
Diroximel fumarate (BIIB098) - Head-to-head trial versus Tecfidera - Relapsing Remitting Multiple Sclerosis (RRMS) Phase 3 Phase 3 top-line data met primary endpoint - July 30, 2019.
ALKS 4230 + Keytruda (ION-01) Head and neck squamous cell cancer Phase 2 Phase 2 trial to be initiated 4Q 2019.
$117.36
-5.7  -4.63%
48.7 million
$5.7 billion
12/06/2019
Tap to view 4 drugs
$31.40
+1.86  +6.30%
121.9 million
$3.8 billion
12/06/2019
Tap to view 4 drugs
Drug Indication Stage News
UCART19 (PALL) Acute lymphoblastic leukemia (ALL) Phase 1 Phase 2 trial to be initiated in 2020.
UCART19 - CALM Refractory B-cell Acute Lymphoblastic Leukaemia Phase 1 Phase 1 trial ongoing.
ALLO-715 Multiple myeloma Phase 1/2 Phase 1/2 trial initiated 3Q 2019.
ALLO-501 - ALPHA Non-Hodgkin lymphoma (NHL) Phase 1 Phase 1 initial data due 1H 2020.
$1.91
-0.04  -2.05%
23.5 million
$44.8 million
12/06/2019
Tap to view 3 drugs
Drug Indication Stage News
Reloxaliase ALLN-177 (URIROX-1) Enteric Hyperoxaluria Phase 3 Phase 3 trial met primary endpoint, key secondary endpoint missed - November 7, 2019.
Reloxaliase ALLN-177 (Study 206) Primary hyperoxaluria Phase 2 Phase 2 presentation at ASN November 8, 2019.
Reloxaliase ALLN-177 (URIROX-2) Enteric Hyperoxaluria Phase 3 Phase 3 data due 2H 2021. Noted December 4, 2019 that it intends to discuss with the FDA a proposal to reduce target enrolment and conduct an earlier interim analysis.
$123.76
-0.47  -0.38%
111.5 million
$13.8 billion
12/06/2019
Tap to view 16 drugs
Drug Indication Stage News
Givosiran Acute hepatic porphyrias Approved FDA approval announced November 20, 2019.
Inclisiran - ORION-9 Hypercholesterolemia Phase 3 Phase 3 data met all endpoints - September 25, 2019. Data November 18, 2019 noted LDL-C reductions of 50%.
ALN-HBV02 (VIR-2218) Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 additional data due 1H 2020.
Lumasiran (ALN-GO1) ILLUMINATE-A Primary Hyperoxaluria Type 1 (PH1) Phase 3 Phase 3 data due late-2019.
Patisiran Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Approved FDA Approval announced August 10, 2018.
ALN-CC5 (cemdisiran) IgA nephropathy Phase 2 Phase 2 trial ongoing.
Fitusiran (ATLAS) Hemophilia Phase 3 Phase 3 ongoing.
ALN-TTRsc02 - HELIOS-A ATTR amyloidosis Phase 3 Phase 3 trial enrolling - noted December 6, 2018.
Inclisiran - ORION-10 Cardiovascular disease (ASCVD) Phase 3 Phase 3 data met all endpoints - September 25, 2019. Detailed data due at AHA noted 58% LDL-C lowering.
Inclisiran - ORION 11 Cardiovascular disease (ASCVD) Phase 3 Phase 3 trial met all primary and secondary efficacy endpoints. Noted September 2, 2019 a 54% LDL-C lowering after 11 months and 50% over 18 months.
ALN-AAT02 alpha-1 anti-trypsin deficiency-associated liver disease Phase 1/2 Phase 1/2 data due late-2019.
Lumasiran (ALN-GO1) ILLUMINATE-B Primary Hyperoxaluria Type 1 Phase 3 Phase 3 top-line data due mid-2020.
Patisiran APOLLO-B Wild-type ATTR amyloidosis patients with cardiomyopathy Phase 3 Phase 3 enrolment to be completed late-2020.
Lumasiran (ALN-GO1) ILLUMINATE-C Impaired renal function Phase 3 Phase 3 trial data due end of 2020.
ALN-AGT Hypertension Phase 1 Phase 1 trial ongoing.
ALN-TTRsc02 (vutrisiran) - HELIOS-B ATTR amyloidosis with cardiomyopathy Phase 3 Phase 3 trial has been initiated - noted November 22, 2019.
$3.07
+0.1  +3.37%
18.6 million
$57.1 million
12/06/2019
Tap to view 3 drugs
Drug Indication Stage News
N91115 Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein Phase 2 Phase 2 data released February 24, 2017 - primary endpoint not met.
ALPN-101 Healthy volunteers Phase 1 Phase 1 presentation at ASH December 8, 2019: 11:00 AM ET.
ALPN-202 Advanced Malignancies Phase 1 Phase 1 trial to be initiated 1Q 2020.
$0.50
+0.02  +3.38%
27.8 million
$13.8 million
12/06/2019
Tap to view 5 drugs
Drug Indication Stage News
ALRN-6924 Peripheral T-cell lymphoma (PTCL) Phase 2a Noted that development to be discontinued - no pivotal trial.
ALRN-6924 and Cytarabine (Ara-C) Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS) Phase 1b Phase 1/1b trial ongoing.
ALRN-6924 and IBRANCE (palbociclib) Solid tumors Phase 2a Phase 2a final data due 2Q 2020.
ALRN-6924 and Paclitaxel Breast cancer Phase 1 Phase 1 has been initiated.
ALRN-6924 Small Cell Lung Cancer (SCLC) Phase 1/2 Phase 1b/2 dose-optimization data due 2Q 2020.
$1.88
+0.05  +2.73%
15.3 million
$28.8 million
12/06/2019
Tap to view 4 drugs
Drug Indication Stage News
HepTCell Hepatitis B Phase 1 Phase 2 trial planned for 2020.
NasoVAX Flu vaccine Phase 2 Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.
NASOSHIELD Anthrax Phase 1b Phase 1b trial to be initiated in 1Q 2020.
ALT-801 Non-alcoholic steatohepatitis (NASH) Phase 1 IND to be filed in 2020 with Phase 1 data due 2021.
$113.89
+6.47  +6.02%
221.3 million
$25.2 billion
12/06/2019
Tap to view 17 drugs
Drug Indication Stage News
CAEL‐101 AL amyloidosis Phase 2/3 Phase 2b/3 trial to be initiated 1H 2020 with data due in 2021.
ACH-4471 C3 glomerulopathy (C3G) Phase 2 Phase 2 completion due 2020.
Eculizumab Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Approved FDA Approval announced June 27, 2019.
ULTOMIRIS (ravulizumab-cwvz) atypical Hemolytic Uremic Syndrome (aHUS) Approved FDA Approval announced October 18, 2019.
ULTOMIRIS (ravulizumab-cwvz) Paroxysmal nocturnal hemoglobinuria (PNH) Approved FDA approval announced December 21, 2018.
Eculizumab Refractory generalized myasthenia gravis (gMG) Approved Approval announced October 23, 2017.
Danicopan (ACH-4471) Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 presentation at ASH December 9, 2019 at 6pm ET.
ACH-5228 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1 Phase 2 trial planned to commence 1H 2020.
ALXN1840 (WTX101) Wilson disease Phase 3 Phase 3 top-line data due 1H 2021.
ULTOMIRIS (ravulizumab-cwvz) Generalized myasthenia gravis (gMG) Phase 3 Phase 3 trial initiated 1Q 2019.
ALXN1830 Warm autoimmune hemolytic anemia (WAIHA) Phase 1/2 Phase 2/3 trial to be initiated early 2020.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) Phase 3 Phase 3 PK data due 1H 2020.
Elamipretide Leber’s hereditary optic neuropathy (LHON) Phase 2 Phase 2 trial did not meet primary endpoint. Phase 3 trial planned for 2020.
Elamipretide Primary mitochondrial myopathy Phase 3 Phase 3 data due January 2020.
ULTOMIRIS Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) Phase 3 Phase 3 trial to commence 1H 2020.
Eculizumab Generalized myasthenia gravis (gMG) - children Phase 3 Phase 3 trial has commenced - noted October 23, 2019.
Eculizumab Neuromyelitis Optica Spectrum Disorder (NMOSD) - children Phase 3 Phase 3 trial to commence by the end of 2019.
$11.07
+0.36  +3.36%
33.9 million
$375.4 million
12/06/2019
Tap to view 6 drugs
Drug Indication Stage News
AMAG-423 / Digoxin immune fab (DIF) Severe preeclampsia in pregnant women Phase 2/3 Phase 2/3 top-line data due 1H 2020.
Vyleesi (Bremelanotide) Female sexual dysfunction (FSD) Approved FDA approval announced June 21, 2019.
Feraheme Adults with iron deficiency anemia (IDA) Approved Approval for sNDA filing announced February 5, 2018.
Makena - auto injector Reduce the risk of preterm birth in women with a singleton pregnancy Approved Approval announced February 14, 2018.
Makena Preterm birth Phase 3 Advisory Committee voted 9-7 recommending withdrawal from market - October 29, 2019.
Ciraparantag Anticoagulated reversal agent / Healthy volunteers Phase 2 End of Phase 2 trial meeting slated for 2H 2020.
AMGN Amgen Inc.
$233.77
+0.36  +0.15%
594.2 million
$138.9 billion
12/06/2019
Tap to view 35 drugs
Drug Indication Stage News
Tezepelumab - NAVIGATOR Asthma Phase 3 Phase 3 data due late-2020.
Prolia (denosumab) Glucocorticoid-induced osteoporosis (GIOP) Approved Approval announced May 21, 2018.
KYPROLIS (ASPIRE) Relapsed Multiple Myeloma Approved sNDA approval announced June 11, 2018.
Vectibix (Panitumumab) Wild-Type RAS Metastatic Colorectal Cancer Approved sBLA approval announced June 29, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) PDUFA Approved September 14, 2017.
Corlanor Chronic Heart Failure Approved Approved April 15, 2015.
Erenumab Migraine Approved Approval announced May 17, 2018.
CNP 520 Alzheimer’s Disease Phase 3 Phase 3 ongoing. Expected completion 2024.
OTEZLA Scalp Psoriasis sNDA Filing sNDA filing pending.
OTEZLA - PSA-006 Psoriatic Arthritis Phase 3 Phase 3 - primary endpoint met.
OTEZLA Behçet’s Disease Approved FDA Approval announced July 19, 2019.
Repatha Cardiovascular disease Approved Approval announced December 1, 2017.
XGEVA Multiple Myeloma Approved sBLA approval announced January 5, 2017.
KYPROLIS (ARROW) Multiple Myeloma Approved FDA approval announced October 1, 2018.
KYPROLIS (ENDEAVOR) Relapsed Multiple Myeloma Approved sNDA approved January 17, 2018.
BLINCYTO Ph+ R/R ALL Approved PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma BLA Filing BLA filing due 1Q 2020.
ABP 980 (Kanjinti; trastuzumab-anns) Herceptin biosimilar CRL FDA approval announced June 13, 2019.
ABP 710 REMICADE biosimilar - rheumatoid arthritis Approved FDA Approval announced December 6, 2019.
Parsabiv Secondary hyperparathyroidism (SHPT) Approved Approved February 7, 2017.
EVENITY (Romosozumab) Osteoporosis Approved FDA Approval announced April 9, 2019.
Omecamtiv mecarbil GALACTIC-HF Acute heart failure Phase 3 Phase 3 interim analysis 1H 2020.
Omecamtiv mecarbil METEORIC-HF Acute heart failure Phase 3 Second Phase 3 trial initiation announced February 21, 2019. Enrolment to continue through 2020.
AMG 420 Relapsed. Refractory (R/R) Multiple Myeloma (MM) Phase 1 Phase 1 data ASCO June 2, 2019. Overall response rate 70% (7/10) in high dose, 13/42 response across all cohorts.
AMG 330 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Phase 1 Phase 1 data at ASH December 1, 2018 noted 12.5% ORR.
Nplate (Romiplostim) Immune Thrombocytopenia (Pediatric) Approved FDA approval announced December 14, 2018.
Nplate (Romiplostim) Immune thrombocytopenia (ITP) Approved FDA Approval announced October 18, 2019.
KYPROLIS (CANDOR) Multiple Myeloma Phase 3 Phase 3 data met primary endpoint - September 13, 2019. LBA at ASH December 10, 2019, 7:30 AM.
OTEZLA - ADVANCE Plaque psoriasis Phase 3 Phase 3 trial is initiating.
AMG 594 Healthy volunteers Phase 1 Phase 1 trial initiation announced February 20, 2019.
AMG 510 Solid tumors Phase 1 Phase 1 update at ESMO noted 54% PR rate for NSCLC patients (960mg); 1/12 for CRC patients. Next update due in 2020.
CNP520 Alzheimer’s Disease Phase 2/3 Phase 2/3 trial discontinued due to lack of efficacy.
BLINCYTO Acute lymphoblastic leukemia (ALL) - pediatric Phase 3 Phase 3 enrolment terminated due to treatment benefit over chemo. Primary endpoint of event-free survival met.
AMG 570 Systemic Lupus Erythematosus (SLE) Phase 2 Phase 2 trial is enrolling.
Tezepelumab Chronic obstructive pulmonary disease (COPD) Phase 2 Phase 2 trial is enrolling.
$0.42
-0.01  -1.98%
158.6 million
$66.6 million
16.03
12/06/2019
Tap to view 2 drugs
Drug Indication Stage News
Ampion Osteoarthritis of the Knee Phase 3 As of July 24, 2019 enrolment has reached approximately 30%.
Optina Diabetic Macula Edema Phase 2b Phase 2b data released May 2015 did not meet endpoints
$18.92
-0.11  -0.58%
46.9 million
$888.1 million
12/06/2019
Tap to view 3 drugs
Drug Indication Stage News
Albuterol DPI Asthma Phase 2b
Naloxone Intranasal Opioid overdose CRL CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol) Asthma CRL CRL issued December 27, 2016.
$22.45
+0.64  +2.93%
358.9 million
$8.1 billion
12/06/2019
Tap to view 1 drug
Drug Indication Stage News
Vascepa High Triglycerides With Mixed Dyslipidemia PDUFA priority review PDUFA date December 28, 2019. Advisory Committee meeting November 14, 2019 voted 16-0 in favor.
$3.68
-0.03  -0.81%
299.1 million
$1.1 billion
3.86
12/06/2019
Tap to view 2 drugs
Drug Indication Stage News
IPX203 Parkinson's disease Phase 3 Phase 3 data due 1H 2020.
K127 Myasthenia Gravis NDA Filing NDA filing planned.
$14.02
-0.21  -1.48%
27.1 million
$380.4 million
12/06/2019
Tap to view 5 drugs
Drug Indication Stage News
ANB020 - etokimab Moderate-to-severe adult atopic dermatitis Phase 2b Phase 2b data failed to meet primary endpoint - November 8, 2019.
ANB020 - etokimab Severe adult eosinophilic asthma Phase 2a Phase 2b trial initiation postponed.
ANB019 Palmo-plantar pustular psoriasis Phase 2 Phase 2 data due 1H 2020.
ANB019 Generalized pustular psoriasis Phase 2 Phase 2 interim data on first TWO patients announced September 30, 2019 with patients reaching primary endpoint. Further data due 2020.
ANB020 - etokimab Nasal polyps Phase 2 Phase 2 data due 1Q 2020.
$1.59
-0.02  -1.30%
7.4 million
$11.8 million
12/06/2019
Tap to view 2 drugs
Drug Indication Stage News
Inodiftagene - Codex Non-muscle invasive bladder cancer (NMIBC) Phase 2 Phase 2 trial discontinued due to lack of efficacy - November 15, 2019.
Inodiftagene with BCG - Leo Non-muscle invasive bladder cancer (NMIBC) Phase 3 Phase 3 planned for 4Q 2019 or 1Q 2020.
$57.48
+0.43  +0.75%
14.3 million
$820.2 million
12/06/2019
Tap to view 3 drugs
Drug Indication Stage News
Cingal Osteoarthritis Phase 3 Phase 3 trial did not meet primary endpoint - June 19, 2018. Further trial to be initiated 1H 2020.
Monovisc Osteoarthritis Approved Approved Feb 2014
HYALOFAST Cartilage defects of the knee Phase 3 Phase 3 enrollment to be completed by the end of 2018.
$3.74
-0.03  -0.80%
20.2 million
$75.6 million
12/06/2019
Tap to view 1 drug
Drug Indication Stage News
Breast cancer vaccine Phase 1
$23.99
-1.86  -7.20%
63.9 million
$1.5 billion
12/06/2019
Tap to view 7 drugs
Drug Indication Stage News
APL-2 subcutaneous Cold agglutinin disease (CAD) Phase 2